Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects

7 dicembre 2021 aggiornato da: Pierre Fabre Dermo Cosmetique

Evaluation of the Cutaneous and Ocular Tolerance of RV4857A Sunscreen Product and Its Efficacy Against the Recurrence of Lesions Post Sun Exposure in Subjects With Facial Acne

The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a monocentric study on adults and adolescents with acne prone skin on the face. This open-labelled study aim first to assess the dermatological and ophthalmological tolerance of the investigational sunscreen product RV4857A formula CD2110 after 28 days and, dermatological tolerance after 57 days of at least a twice daily on the study areas, under normal conditions of use, on 40 subjects intending to have a minimum of 10 days per month of sun exposure duration ≥ 1h, in the time slot 11am-4pm and intending to have a minimum of 4 swimming sessions (sea or swimming pool) during at least the first month of the study.

Secondary objectives :

  • To assess the anti-imperfection efficacy of the product during the summer
  • To assess the "non" rebound effect (non recurrence of acne) one month after stopping the application of the sunscreen and without any sun exposure at D85 (difference between D85 and D0)
  • To evaluate the impact on Quality of Life of subjects through CADI and DLQI questionnaires (or CDLQI questionnaire for adolescent from 12 to 16 years-old) completed at baseline, D29 and D57

The study includes 4 visits :

  • Visit 1: Inclusion visit (D1)
  • Visit 2: Intermediate visit (D29)
  • Visit 3: Intermediate visit "end of summer" (D57), a Stop the application of the sunscreen product (and stop sun exposure) between Visit 3 and the end of the study Visit 4: End of study visit in autumn (D85)

The theoretical study duration for each subject will be 85 days with at least 57 days of product use. The study interest areas are Face and Neck.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

45

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Portogallo
      • Lisboa, Portogallo, 1750-182
        • PhD Trials®

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 40 anni (Bambino, Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

Subjects will be recruited from the investigation centre's panel. The participants will be selected on the basis of inclusion and non-inclusion criteria specific to the study and on their ability to comply with the constraints required by the protocol. The participants will be definitely included in the study after a specific interview and a clinical examination

Descrizione

Inclusion Criteria:

  1. Related to the population:

    • Females and/or males (with at least 25% of male)
    • Age: adults from 18 to 40 years old and adolescent from 12 to 17 years old (33% to 50% of the total population)
    • Considered "healthy subject" by the Investigator
    • Being of Phototype I to IV
    • Subject with combination to oily skin
    • Subject who foresees sun exposure during the first 2 months of the study
    • Subjects must be registered with health social security or health social insurance (if required by national regulations)
    • Subject and/or parent(s)/legal representative(s) who have signed his/her/their written informed consent for his/her participation in the study (or his/her/their child participation in the study) and a photograph authorization
    • For woman of childbearing potential: committing herself to use effective contraceptive method since at least 3 months before the beginning of the study and committing to it throughout the study
    • Regular users of very high protection sunscreen products.

  2. Related to the disease:

    • For adults and adolescents: subject with mild to moderate acne with a total of 10 to 40 acne lesions (at least 5 non-inflammatory lesions (open and closed comedones) and at least 3 to 10 inflammatory lesions (papules and pustules) maximum on the face, excluding the nose area), at the inclusion.
    • Subject prone to have recurrence of acne lesions in autumn (declarative)

Exclusion Criteria:

  1. Related to the population:

    • Having participated in another clinical trial within 4 weeks before the inclusion visit and for a longer period if required in the Investigator's opinion Taking part or planning to participate in another clinical trial during the study in the same or another investigation centre
    • Breastfeeding or pregnant or not willing to take necessary precautions to avoid pregnancy during the study and for at least 3 months before the inclusion visit (for the woman of childbearing potential)
    • Subject or parent(s)/legal representative(s) deprived of freedom by administrative or legal decision or under guardianship
    • Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency
    • Subject admitted in a sanitary or social facility
    • Subject planning a hospitalization during the study

  2. Related to the disease

    • Cutaneous pathology (psoriasis, atopic dermatitis, skin infectious disease of viral, bacterial, fungus or parasitic origin …) or dermatological condition (especially pityriasis versicolor, severe pigmentation disorders) on the studied zone other than acne liable to interfere with the data of the study
    • Severe acne
    • Clinical signs of hormonal disfunctions or hyperandrogenism
    • Excessive exposure to sunlight or UV-rays within the previous month
    • Having history of abnormal reactions from exposure to sunlight
    • Use of self tanning product during the previous month History of hypersensitivity or intolerance to any cosmetic product

  3. Related to treatments

    • Use of a systemic or topical medication with anti-inflammatory or photosensitising products during the previous 2 weeks and for systemic medication with corticoids and/or antihistaminics during the previous 4 weeks
    • Use of a systemic treatment for acne during the previous month for antibiotics, zinc gluconate and hormonal treatment and during the 6 previous months for isotretinoin
    • Use of a topical treatment for acne during the previous month (benzoil peroxide, retinoid, antibiotics, azelaic acid…)
    • Use of anti-acneic or anti-seborrheic cosmestic care (containing alpha hydroxy-acids, retinoic derivatives..) during the 15 previous days
    • Use of other topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous tolerance and efficacy of the studied product (according to the investigator's appreciation)
    • Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study
    • Woman whose oral contraception is instaured or changed for less than 3 months

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
RV4857A arm

Application of the product before and during each sun exposure, at least twice a day.

During sun exposures, the applications were renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, the product was applied in the morning and at the beginning of the afternoon.
Altro: RV4857A
RV4857A formula CD2110 is a sunscreen product

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Assessment of the dermatological physical signs
Lasso di tempo: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
The assessment of the dermatological physical signs is based on a visual examination
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the dermatological functional signs
Lasso di tempo: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
The functional signs is assessed by questioning the subject
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the ophthalmological physical signs
Lasso di tempo: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
The assessment of the ophthalmological physical signs is based on a dermatologist visual examination
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the ophthalmological functional signs
Lasso di tempo: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
The functional signs is assessed by questioning the subject
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the Tear film Break Up Time (BUT)
Lasso di tempo: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
The tear film break-up time is a test to measure the relative stability of the pre-corneal tear film. This examination is performed by the same Ophthalmologist thanks to a biomicroscope after blinking (using a chronometer). The measured time will be expressed in seconds
Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of global tolerance assessment (dermatogical assesment), a 5-point scale
Lasso di tempo: Change from Baseline to 29 and 57 days later
  • Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
  • Very good
  • Good
  • Moderate
  • Bad
Change from Baseline to 29 and 57 days later
Assessment of global tolerance assessment (ophthalmological assessment), a 5-point scale
Lasso di tempo: Change from Baseline to 29 days later
  • Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
  • Very good
  • Good
  • Moderate
  • Bad
Change from Baseline to 29 days later

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change of the number of total acne lesions on the face
Lasso di tempo: Change from Baseline to 29, 57 and 85 days later
by counting according to the method of Lucky
Change from Baseline to 29, 57 and 85 days later
Change of the number of non-inflammatory lesions (open and closed comedones) on the face
Lasso di tempo: Change from Baseline to 29, 57 and 85 days later
by counting according to the method of Lucky
Change from Baseline to 29, 57 and 85 days later
Change of the number of inflammatory lesions (papules, pustules, nodules) on the face
Lasso di tempo: Change from Baseline to 29, 57 and 85 days later
by counting according to the method of Lucky
Change from Baseline to 29, 57 and 85 days later
Assessment of the non-comedogenic potential
Lasso di tempo: Change from Baseline to 29 days later
by statistical comparison of open and closed comedones counted by the investigator on the face before and after 28 days of application of investigational product
Change from Baseline to 29 days later
Change of the acne severity, assess by Global Acne Evaluation (GEA) on a 6-point scale
Lasso di tempo: Change from Baseline to 29, 57 and 85 days later
  • 0: Clear
  • 1: Almost clear
  • 2: Mild
  • 3: Moderate
  • 4: Severe
  • 5 : Very Severe
Change from Baseline to 29, 57 and 85 days later
Evaluation of the global acne evolution on a 6-point scale
Lasso di tempo: Change from Baseline to 29 and 57 days later

-1: Worsening, 0: No change,

  1. Mild improvement,
  2. Moderate improvement,
  3. Good improvement,
  4. Very good improvement
Change from Baseline to 29 and 57 days later
Evaluation of the global product efficacy by the subjects themselves regarding rebound effect in Autumn
Lasso di tempo: Change from Baseline to 85 days later
Questions Q24 and Q25 at D85 in the self-questionnaire
Change from Baseline to 85 days later
Assessment of the cosmetic acceptability and perceived efficacy of the product
Lasso di tempo: Change from Baseline to 29 and 57 days later
The self subject assemsment consists of different questions concerning participants' perception of the product's efficacy (majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one)
Change from Baseline to 29 and 57 days later
To evaluate the impact on Quality of Life of subjects through questionnaires
Lasso di tempo: Change from Baseline to 29 and 57 days later
Quality of Life questionnaires consist of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week
Change from Baseline to 29 and 57 days later

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pierre Fabre Dermo Cosmetique

Investigatori

  • Cattedra di studio: Pedro Contreiras Pinto, PhD, PhD Trials®
  • Investigatore principale: Leonor Girão, MD, PhD Trials®

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 luglio 2020

Completamento primario (Effettivo)

9 novembre 2020

Completamento dello studio (Effettivo)

9 novembre 2020

Date di iscrizione allo studio

Primo inviato

29 settembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

7 dicembre 2021

Primo Inserito (Effettivo)

23 dicembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 dicembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 dicembre 2021

Ultimo verificato

1 dicembre 2021

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • RV4857A202092

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Acne

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Suriname

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi